BioIVT, a global provider of biospecimen solutions for drug and diagnostic development, has entered an exclusive commercial agreement with Handok Biotech Co. LTD.

This partnership will allow Handok to supply researchers in South Korea with access to a broad range of biological materials, supporting advancements in drug discovery, toxicology, development, and personalized medicine.

The agreement grants Handok Biotech exclusive rights to distribute BioIVT’s portfolio in South Korea. This portfolio includes biofluids, tissues, cell products, media, and subcellular fractions and enzymes. Access to these materials is considered essential for enabling diverse areas of life science research.

Dimas Neto, Director of Global Channel Partnerships at BioIVT, noted that the collaboration aims to advance scientific discovery in East Asia and contribute to healthcare improvements globally. Mun-Chul Lee, CEO of Handok Biotech, highlighted that combining Handok’s regional expertise with BioIVT’s product range will offer researchers faster delivery, competitive pricing, and continued technical support.

BioIVT brings over 35 years of experience in sourcing biospecimens, including a donor pool of more than 600 consented individuals in the US and UK. The company provides samples that support precision medicine research by linking clinical data with biological specimens. This agreement with Handok builds on BioIVT’s ongoing efforts to expand strategic partnerships across Asia.

Handok Biotech is part of HANDOK, a Korean pharmaceutical and healthcare company founded in 1954. HANDOK focuses on areas such as diabetes, rare diseases, cardiovascular health, oncology, medical devices, diagnostics, and consumer health products. The company has established several strategic collaborations with multinational pharmaceutical firms.

About BioIVT: BioIVT supplies personalized biospecimen solutions and research services to the life sciences and diagnostics sectors. Its portfolio includes human and animal tissues, ADME products, cell and gene therapy materials, blood, and other biofluids. By providing clinical specimens alongside detailed donor data, BioIVT supports precision medicine initiatives aimed at improving patient outcomes.

Handok Biotech is dedicated to delivering healthcare solutions in Korea and aims to enhance quality of life through innovative products in pharmaceuticals and diagnostics. The company has a history of partnerships with international pharmaceutical firms and a strong regional presence.